Oxidized low-density lipoprotein (Ox-LDL) not LDL antiphospholipid syndrome (APS)

Clinical and Experimental Immunology

Volumn 108, Issue 2, 1997, Pages 227-233

  George, J ^a,b   Blank, M ^a,b   Hojnik, M ^a,b   Bar Meir, E ^a,b   Koike, T ^c   Matsuura, E ^c   Lorber, M ^d   Aviram, M ^d   Shoenfeld, Y ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HOKKAIDO UNIVERSITY   (Japan)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

anticardiolipin antibodies; antiphospholipid syndrome; autoantibodies; autoimmunity; low density lipoproteins

Indexed keywords

CARDIOLIPIN ANTIBODY; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY;

ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; CROSS REACTION; DISEASE SEVERITY; FEMALE; FETUS RESORPTION; FOAM CELL; LIPID PEROXIDATION; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOEMBOLISM;

EID: 0030982089     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.d01-1019.x     Document Type: Article

References (36)

1. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13:486-9.
2. Hughes GRV. The antiphospholipid syndrome: 10 years on. Lancet 1993; 342:341-4.
3. Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996; 93:1579-87.
4. Levine SR, Deegan MJ, Futrell N, Welch KMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990; 40:1181-9.
5. Amigo MC, Garcia-Torres R, Robles M, Bochicchio T, Reyes PA. Renal involvement in primary antiphospholipid syndrome. J Rheumatol 1992; 19:1181-5.
6. Grob JJ, Bonerandi JJ. Thrombotic skin disease as a marker of the anticardiolipin syndrome. J Am Acad Dermatol 1989; 20:1063-9.
7. Asherson RA, Cervera R. 'Primary', 'secondary' and other variants of the antiphospholipid syndrome. Lupus 1994; 3:293-8.
8. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4.
9. Galli M, Comfurius P, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335:1544-7.
10. Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naive mice with lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 1991; 88:3069-73.
11. Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992; 89:1558-63.
12. Shibata S, Harpel PC, Gharavi A, Rand J, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994; 83:2532-40.
13. Shibata S, Sasaki T, Harpel P, Fillit H. Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes. Clin Immunol Immunopathol 1994; 70:114-23.
14. Sammaritano LR, Gharavi AE, Soberano C, Levy RA, Lockshin MD. Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein. J Clin Immunol 1992; 12:27-35.
15. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341:923-5.
16. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88:1785-92.
17. Aviram M. Modified forms of low density lipoprotein and atherosclerosis. Atherosclerosis 1993; 98:1-9.
18. Aviram M. Macrophage-mediated oxidation of LDL and atherosclerosis. In: Bellomo G, Finardi G, Rice-Evans C, eds. Free radicals, lipoprotein oxidation and atherosclerosis: biological and clinical aspects, Vol. IX. London: Richelieu Press, 1993:101-37.
19. Aviram M. LDL-platelet interaction under oxidative stress induced macrophage foam cell formation. Thromb Haemostasis 1995; 74:560-4.
20. Chisolm GM, Ma G, Irwin KC et al. 7β-hydroperoxicholest-5-N3β-ol, a component of human atherosclerotic lesions is the primary cytotoxin of oxidized human low density lipoprotein. Proc Natl Acad Sci USA 1994; 91:11452-6.
21. Coffey MD, Cole RA, Colles SM, Chisolm GM. In vitro cell injury by oxidized low density lipoprotein involves lipid hydroperoxide-induced formation of alkoxyl, lipid and peroxyl radicals. J Clin Invest 1995; 96:1866-73.
22. Galle J, Mulsch A, Busse R, Bassenge E. Effects of native and oxidized low density lipoproteins on formation and activation of endothelial derived relaxing factor. Arterioscler Thromb 1991; 11:198-203.
23. 1 mouse model for antiphospholipid syndrome cross-react with oxidized low-density lipoprotein. Arthritis Rheum 1995; 38:1382-8.
24. Sutjita MA, Hohmman R, Comacchio R, Boey ML, Bradley JA. A common anti-cardiolipin antibody idiotype in autoimmune disease: identification using a mouse monoclonal antibody directed against a naturally occurring antiphospholipid antibody. Clin Exp Immunol 1988; 74:110-4.
25. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179:457-62.
26. 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154:954-60.
27. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, deGroot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81:2618-25.
28. Khoo JC, Miller E, Pio F, Steinberg D, Witztum JL. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb 1992; 12:1258-66.
29. Wu R, Lefvert AK. Autoantibodies against oxidized low density lipoproteins (Ox-LDL): characterization of antibody isotype, subclass, affinity and effect on macrophage uptake of Ox-LDL. Clin Exp Immunol 1995; 102:174-80.
30. Yla-Hettuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994; 14:32-40.
31. Salonen JT, Yia-Herttuala S, Yamamoto R et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339:883-7.
32. Puurunen M, Manttari M, Manninen Vesa et al. Antibodies against oxidized low density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154:2605-9.
33. Branch DW, Mitchell MD, Miller E, Palinski W, Witzum JL. Preeclampsia and serum antibodies to oxidized low density lipoproteins. Lancet 1994; 343:645-6.
34. Parmus DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990; 114:383-7.
35. 2-glycoprotein as an anticardiolipin cofactor determined using deleted mutants expressed by a baculovirus system. Blood 1996; 87:3262-70.
36. Polz E, Kostner GM. The binding of β2GPI to human serum lipoproteins. Distribution among density fraction. FEBS Letters 1979; 102:183-6.